Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update


RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies

View post:
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

Related Posts